Last reviewed · How we verify
P16_37-63 peptide without Montanide® ISA-51 VG
P16_37-63 peptide without Montanide® ISA-51 VG is a Biologic drug developed by Oryx GmbH & Co. KG. It is currently in Phase 1 development.
At a glance
| Generic name | P16_37-63 peptide without Montanide® ISA-51 VG |
|---|---|
| Sponsor | Oryx GmbH & Co. KG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P16_37-63 peptide without Montanide® ISA-51 VG CI brief — competitive landscape report
- P16_37-63 peptide without Montanide® ISA-51 VG updates RSS · CI watch RSS
- Oryx GmbH & Co. KG portfolio CI
Frequently asked questions about P16_37-63 peptide without Montanide® ISA-51 VG
What is P16_37-63 peptide without Montanide® ISA-51 VG?
P16_37-63 peptide without Montanide® ISA-51 VG is a Biologic drug developed by Oryx GmbH & Co. KG.
Who makes P16_37-63 peptide without Montanide® ISA-51 VG?
P16_37-63 peptide without Montanide® ISA-51 VG is developed by Oryx GmbH & Co. KG (see full Oryx GmbH & Co. KG pipeline at /company/oryx-gmbh-co-kg).
What development phase is P16_37-63 peptide without Montanide® ISA-51 VG in?
P16_37-63 peptide without Montanide® ISA-51 VG is in Phase 1.